Copyright
©The Author(s) 2021.
World J Clin Cases. Dec 6, 2021; 9(34): 10484-10493
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10484
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10484
Table 1 The characteristics of patients with two malignancies, n (%)
Characteristics | Synchronous MPM | Metachronous MPM | Total |
Patients | 51 (23.0) | 171 (77.0) | 222 (100) |
Gender | |||
Male | 32 (62.7) | 87 (50.9) | 119 (53.6) |
Female | 19 (37.3) | 84 (49.1) | 103 (46.4) |
Age in yr, median (range) | |||
First cancer | 62 (32-84) | 55 (19-87) | 56 (19-87) |
Second cancer | 62 (32-84) | 64 (28-90) | 64 (28-90) |
The most common sites in first primary cancers | |||
1st | Esophagus, 9 (17.6) | Breast, 31 (18.1) | Breast, 33 (14.9) |
2nd | Colorectum, 8 (15.7) | Colorectum, 23 (13.7) | Colorectum, 31 (14.0) |
3rd | Bladder/thyroid/hypopharynx, 4 (7.8), respectively | Stomach, 14 (8.2) | Stomach, 17 (7.7) |
The most common sites in second primary cancers | |||
1st | NSCLC, 12 (23.5) | NSCLC, 54 (31.6) | NSCLC,66 (29.7) |
2nd | Stomach, 9 (17.6) | Stomach, 15 (8.8) | Stomach, 24 (10.8) |
3rd | Esophagus/kidney, 6 (11.8), respectively | Liver, 13 (7.6) | Esophagus/liver, 16 (7.2), respectively |
Median interval (range) between the first and second cancers (mo) | 0.2 (0-5.9) | 73.2 (6.3-536.8) | 43.6 (0-536.8) |
Metastasis | 16 (31.4) | 83 (48.5) | 99 (44.6) |
Median overall survival in mo | 36.4 | 35.3 | 35.4 |
Table 2 The most common multiple primary malignancies in patients with two malignancies
Malignancies | Total | Synchronous MPM | Metachronous MPM | Median OS in mo |
NSCLC and breast cancer | 12 | 2 | 10 | 79.8 |
NSCLC and gastric cancer | 10 | 0 | 10 | 16.7 |
Colorectal cancer and gastric cancer | 10 | 3 | 7 | Not reached |
Esophageal cancer and gastric cancer | 9 | 6 | 3 | 36.2 |
NSCLC and bladder cancer | 7 | 2 | 5 | 31.2 |
NSCLC and cervical cancer | 6 | 1 | 5 | 35.5 |
NSCLC and thyroid cancer | 6 | 2 | 4 | Not reached |
NSCLC and colorectal cancer | 6 | 1 | 5 | Not reached |
NSCLC and esophageal cancer | 6 | 3 | 3 | Not reached |
Table 3 Univariate analysis and multivariate analysis of the prognostic factors of overall survival in patients with two malignancies
Factors | Cases | Univariate analysis | Multivariate analysis | |||
Median OS in mo | P | HR | 95%CI | P | ||
Gender | 0.114 | |||||
Male | 119 | 31.2 | ||||
Female | 103 | 37.1 | ||||
Age at second cancer (yr) | 0.038 | 1.016 | 1.000-1.032 | 0.046 | ||
≤ 65 | 128 | 36.4 | ||||
> 65 | 94 | 28.4 | ||||
Metastasis | 0.000 | 4.291 | 2.743-6.710 | 0.000 | ||
No | 123 | 86.9 | ||||
Yes | 99 | 20.4 | ||||
MPM | 0.809 | |||||
Synchronous | 51 | 36.4 | ||||
Metachronous | 171 | 35.3 |
Table 4 The clinical features of 21 patients with three malignancies
Case | Sex | First cancer | Second cancer | Third cancer | Metastases | Outcome | OS since third cancer in mo |
1 | M | Parotid cancer | Colon cancer | Penile cancer | Yes | Dead | 0.6 |
2 | F | Small cell lung cancer | Colon cancer | Soft tissue sarcoma | No | Dead | 14.4 |
3 | M | Gastric cancer | Liver cancer | Rectal cancer | Yes | Dead | 14.0 |
4 | M | Rectal cancer | Renal cancer | Colon cancer | No | Alive | 23.1 |
5 | M | Colon cancer | Bladder cancer | Renal pelvis cancer | No | Alive | 67.5 |
6 | F | Soft tissue sarcoma | Colon cancer | Bladder cancer | Yes | Dead | 4.8 |
7 | F | Colon cancer | Endometrial cancer | Breast cancer | Yes | Alive | 23.8 |
8 | F | Breast cancer | Parotid cancer | Neuroendocrine carcinoma | Yes | Dead | 9.5 |
9 | M | Bladder cancer | Thyroid cancer | Ureteral cancer | No | Alive | 18.9 |
10 | M | Rectal cancer | Colon cancer | Cholangiocarcinoma | Yes | Dead | 6.0 |
11 | M | Laryngeal cancer | Esophageal cancer | Non-small cell lung cancer | No | Alive | 21.5 |
12 | M | Thyroid cancer | Laryngeal cancer | Rectal cancer | Yes | Dead | 10.2 |
13 | M | Bladder tumor | Colon cancer | Non-small cell lung cancer | No | Dead | 12.7 |
14 | M | Laryngeal cancer | Renal pelvis cancer | Bladder cancer | No | Dead | 12.9 |
15 | F | Rectal cancer | Thyroid cancer | Breast cancer | Yes | Dead | 95.4 |
16 | F | Skin squamous cell carcinoma | Skin basal cell carcinoma | Endometrial cancer | Yes | Alive | 57.7 |
17 | F | Gallbladder cancer | Endometrial cancer | Rectal cancer | No | Alive | 15.4 |
18 | F | Endometrial cancer | Rectal cancer | Pancreatic cancer | Yes | Dead | 6.0 |
19 | F | Breast cancer | Thymic cancer | Choriocarcinoma | No | Alive | 18.8 |
20 | F | Breast cancer | Thyroid cancer | Liver cancer | Yes | Alive | 9.0 |
21 | M | Prostate cancer | Gastric cancer | Colon cancer | Yes | Dead | 7.9 |
Table 5 The characteristics of patients with three malignancies, n (%)
Characteristics | n (%) |
Total | 21 |
Gender | |
Male | 11 (52.4) |
Female | 10 (47.6) |
Age in yr, median (range) | |
First cancer | 47 (18-74) |
Second cancer | 54 (33-87) |
Third cancer | 57 (34-89) |
The most common cancers | |
Colon cancer | 9 (14.3) |
Rectal cancer | 7 (11.1) |
Breast cancer | 5 (7.9) |
Bladder/endometrial/thyroid cancer | 4 (6.3), respectively |
Laryngeal cancer | 3 (4.8) |
Metastasis | 12 (57.1) |
Median OS since third cancer in mo | 14.4 |
- Citation: Wang XK, Zhou MH. Clinical features and survival of patients with multiple primary malignancies. World J Clin Cases 2021; 9(34): 10484-10493
- URL: https://www.wjgnet.com/2307-8960/full/v9/i34/10484.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i34.10484